Dopamine and DBS accelerate the neural dynamics of volitional action in Parkinson’s disease

Richard M. Köhler,Thomas S. Binns,Timon Merk,Guanyu Zhu,Zixiao Yin,Baotian Zhao,Meera Chikermane,Jonathan Vanhoecke,Johannes L. Busch,Jeroen G.V. Habets,Katharina Faust,Gerd-Helge Schneider,Alessia Cavallo,Stefan Haufe,Jianguo Zhang,Andrea A. Kühn,John-Dylan Haynes,Wolf-Julian Neumann

DOI: https://doi.org/10.1101/2023.10.30.564700

2024-02-08

Abstract:The ability to initiate volitional action is fundamental to human behaviour. Loss of dopaminergic neurons in Parkinson’s disease is associated with impaired action initiation, also termed akinesia. Both dopamine and subthalamic deep brain stimulation (DBS) can alleviate akinesia, but the underlying mechanisms are unknown. An important question is whether dopamine and DBS facilitate de novo build-up of neural dynamics for motor execution or accelerate existing cortical movement initiation signals through shared modulatory circuit effects. Answering these questions can provide the foundation for new closed-loop neurotherapies with adaptive DBS, but the objectification of neural processing delays prior to performance of volitional action remains a significant challenge. To overcome this challenge, we studied readiness potentials and trained brain signal decoders on invasive neurophysiology signals in 25 DBS patients (12 female) with Parkinson’s disease during performance of self-initiated movements. Combined sensorimotor cortex electrocorticography (ECoG) and subthalamic local field potential (LFP) recordings were performed OFF therapy ( =22), ON dopaminergic medication ( =18) and ON subthalamic deep brain stimulation ( =8). This allowed us to compare their therapeutic effects on neural latencies between the earliest cortical representation of movement intention as decoded by linear discriminant analysis classifiers and onset of muscle activation recorded with electromyography (EMG). In the hypodopaminergic OFF state, we observed long latencies between motor intention and motor execution for readiness potentials and machine learning classifications. Both, dopamine and DBS significantly shortened these latencies, hinting towards a shared therapeutic mechanism for alleviation of akinesia. To investigate this further, we analysed directional cortico-subthalamic oscillatory communication with multivariate granger causality. Strikingly, we found that both therapies independently shifted cortico-subthalamic oscillatory information flow from antikinetic beta (13-35 Hz) to prokinetic theta (4-10 Hz) rhythms, which was correlated with latencies in motor execution. Our study reveals a shared brain network modulation pattern of dopamine and DBS that may underlie the acceleration of neural dynamics for augmentation of movement initiation in Parkinson’s disease. Instead of producing or increasing preparatory brain signals, both therapies modulate oscillatory communication. These insights provide a link between the pathophysiology of akinesia and its’ therapeutic alleviation with oscillatory network changes in other non-motor and motor domains, e.g. related to hyperkinesia or effort and reward perception. In the future, our study may inspire the development of clinical brain computer interfaces based on brain signal decoders to provide temporally precise support for action initiation in patients with brain disorders.

Neuroscience

What problem does this paper attempt to address?

The paper primarily explores the changes in brain neurodynamics in Parkinson's disease patients during self-initiated movements and investigates how dopamine and subthalamic nucleus deep brain stimulation (DBS) accelerate this neurodynamic process.

Specifically, the study attempts to answer the following core questions:
1. **Can dopamine and DBS accelerate neurodynamics to facilitate the initiation of movement?** Researchers aim to understand whether these two therapies accelerate the neurodynamic construction of new movements by enhancing the existing cortical motor initiation signals or through shared regulatory pathway effects.
2. **What are the specific mechanisms of dopamine and DBS in initiating movement?** By comparing the effects of these therapies on the delay from the earliest appearance of motor intention to the onset of muscle activation, the study explores their common mechanisms in alleviating akinesia.
3. **How do dopamine and DBS alter the oscillatory characteristics of brain networks?** Researchers analyze how the two therapies independently shift the oscillatory information flow between the cortex and subthalamic nucleus from the anti-movement β band (13-35 Hz) to the pro-movement θ band (4-10 Hz).

To answer these questions, the research team conducted electrocorticography (ECoG) and subthalamic nucleus local field potential (LFP) recordings on 25 Parkinson's disease patients, who were either untreated, taking dopamine medication, or receiving subthalamic nucleus DBS. The study used machine learning classifiers to decode invasive neurophysiological signals related to motor intention, quantifying the neural delay before movement execution, and analyzing how dopamine and DBS affect the directionality of cortical-subthalamic oscillatory communication. The results showed that both dopamine and DBS significantly reduced the delay time between motor intention and movement execution, and both therapies independently promoted the shift of oscillatory information flow from the anti-movement β band to the pro-movement θ band from the cortex to the subthalamic nucleus. These findings provide important insights into the pathophysiology of movement initiation disorders in Parkinson's disease and their therapeutic mechanisms, potentially inspiring future brain-machine interface-based clinical applications.